Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
September 2021
-
Media Release
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks… -
Media Release
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive… -
Photographer Captures Patients Around the World Persevering With ITP
To showcase how people living with ITP triumph and persevere, Novartis partnered with photographer Kate T. Parker on a series of photo essays.
-
Toward regrowing cartilage
Novartis researchers aim to improve the lives of patients with osteoarthritis.
-
Doing the right thing is good business
Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.
-
Media Release
Novartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer
Biologics License Application (BLA) submission supported by Phase III RATIONALE 302 trial, which met primary endpoint of improvement in overall survival (OS) in people with advanced or metastatic… -
Media Release
Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading… -
A blood cancer patient’s long road to diagnosis
Ilona, a patient living with polycythemia vera, shares her experiences with this rare blood cancer
-
Pulse Update
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Media Release
Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions
Novartis will present 12 abstracts at the European Respiratory Society (ERS) International Congress 2021 for Enerzair® Breezhaler® (IND/GLY/MF*) and Atectura® Breezhaler® (IND/MF**) — for… -
Pulse Update
Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
-
Media Release
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)
Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three…
Pagination
- ‹ Previous page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- …
- 154
- › Next page
Test disclaimer...!!!